Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × Tamoxifen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 227 Carcinoma, Intraductal, Noninfiltrating 20 Breast Carcinoma In Situ 17 Neoplasm Metastasis 12 Neoplasms 11 Breast Neoplasms, Male 11 Ovarian Neoplasms 8 Inflammatory Breast Neoplasms 6 Glioblastoma 5 Endometrial Neoplasms 4 Central Nervous System Neoplasms 4 Breast Cancer Female 4 Prostatic Neoplasms 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Glioma 2 Fibroadenoma 2 ER+ Breast Cancer 2 Carcinoma, Lobular 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Wake Disorders 1

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 13 lanreotide 12 gallium Ga 68 dotatate 12 Temozolomide 11 Octreotide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 8 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 pasireotide 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 avelumab 4 Somatostatin 4 Ipilimumab 4 Injections 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡